When Pfizer discontinued Exubera, its disastrously unsuccessful inhaled insulin, in 2007, the soul searching wasn't limited to Manhattan's East 42nd Street.
BLAIR JACKSON
Vice President of Business Development and New Product Planning, Alkermes
(JOHN HALPERN)
When Pfizer discontinued Exubera, its disastrously unsuccessful inhaled insulin, in 2007, the soul searching wasn't limited to Manhattan's East 42nd Street. One of the companies that found itself reeling was Alkermes, a biotech with deep experience in drug delivery, which had been partnering with Lilly on a prospective inhaled insulin product—one that Lilly cancelled not long after Exubera bit the dust."That caused us to really take stock of what we were doing and how we were moving forward," recalls Blair Jackson. At the time the Lilly project was pulled, Alkermes had only one proprietary program in development, Vivitrol (naltrexone) for alchohol dependency; the rest of the company's resources were focused on developing drugs for partners. Suddenly that ratio looked wrong. "Over the course of the next year," says Jackson, "we moved from being a single- to a multiple-product developing company. We ended up doing more than 25 clinical and nonclincal studies. We had five or six regulatory filings. It was a fundamental shift in the organization." And leading the way was Jackson's program leadership team. The lessons of turning the battleship? "One of the most important things is flexibility," says Jackson. "When you look at severeal development programs at once, you find that the plan going in at the beginning of the year is completely different from the plan coming out at the back end. But what does remain the same is the budget."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.